Fuelling innovation
Avedro, Inc has has secured $25 million in financing
Colin Kerr
Published: Friday, June 1, 2018
Avedro, Inc has announced that it has secured $25 million in financing led by Lilly Asia Ventures (LAV)
with major participation from existing investors OrbiMed Advisors, InterWest Partners and HealthQuest Capital.
“Avedro’s mission is to develop non-invasive corneal remodelling treatments that protect and improve vision and dramatically better patients’ lives,” said Reza Zadno, PhD, CEO of Avedro.
“This new funding brings together an exceptional syndicate of investors who are committed to helping us achieve this goal.”
www.Avedro.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.